WO2002102375A3 - Derives d'imidazoles modulant les canaux sodiques - Google Patents

Derives d'imidazoles modulant les canaux sodiques Download PDF

Info

Publication number
WO2002102375A3
WO2002102375A3 PCT/FR2002/002039 FR0202039W WO02102375A3 WO 2002102375 A3 WO2002102375 A3 WO 2002102375A3 FR 0202039 W FR0202039 W FR 0202039W WO 02102375 A3 WO02102375 A3 WO 02102375A3
Authority
WO
WIPO (PCT)
Prior art keywords
sodium channels
imidazole derivatives
modulating sodium
alkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2002/002039
Other languages
English (en)
Other versions
WO2002102375A2 (fr
Inventor
Dennis Bigg
Jacques Pommier
Anne-Marie Liberatore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0400195A priority Critical patent/HUP0400195A3/hu
Priority to AT02745529T priority patent/ATE304354T1/de
Priority to EP02745529A priority patent/EP1401432B1/fr
Priority to US10/480,977 priority patent/US7157483B2/en
Priority to MXPA03011508A priority patent/MXPA03011508A/es
Priority to KR10-2003-7016257A priority patent/KR20040030672A/ko
Priority to DE60206171T priority patent/DE60206171T2/de
Priority to NZ529741A priority patent/NZ529741A/en
Priority to CA002449916A priority patent/CA2449916A1/fr
Priority to BR0210285-4A priority patent/BR0210285A/pt
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to JP2003504962A priority patent/JP2005500297A/ja
Publication of WO2002102375A2 publication Critical patent/WO2002102375A2/fr
Publication of WO2002102375A3 publication Critical patent/WO2002102375A3/fr
Priority to IS7067A priority patent/IS2367B/is
Priority to NO20035553A priority patent/NO20035553D0/no
Anticipated expiration legal-status Critical
Priority to US11/281,864 priority patent/US7402602B2/en
Priority to US11/604,522 priority patent/US20070099975A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Networks Using Active Elements (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Control Of Transmission Device (AREA)
  • Molds, Cores, And Manufacturing Methods Thereof (AREA)

Abstract

Selon l'invention, les composés de formule générale (I) dans laquelle Rl représente un radical alkyle, cycloalkylalkyle ou aralkyle éventuellement substitué sur le groupe aryle; R2 représente un radical phényle éventuellement substitué ou encore R2 représente un radical biphényle éventuellement substitué; R3 représente un atome d'hydrogène ou un radical alkyle; et les sels pharmaceutiquement acceptables de ces derniers; peuvent être utilisés pour préparer un médicament destiné à moduler les canaux sodiques, et notamment à traiter la douleur (par exemple la douleur d'origine neuropathique), l'épilepsie, des troubles liés à la neurodégénération ou des troubles bipolaires.
PCT/FR2002/002039 2001-06-14 2002-06-14 Derives d'imidazoles modulant les canaux sodiques Ceased WO2002102375A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
AT02745529T ATE304354T1 (de) 2001-06-14 2002-06-14 Kaliumkanal-modulierende imidazolderivate
EP02745529A EP1401432B1 (fr) 2001-06-14 2002-06-14 Derives d'imidazoles modulant les canaux sodiques
US10/480,977 US7157483B2 (en) 2001-06-14 2002-06-14 Imidazole derivatives modulating the sodium channels
MXPA03011508A MXPA03011508A (es) 2001-06-14 2002-06-14 Derivados de imidazol que modulan los canales de sodio.
KR10-2003-7016257A KR20040030672A (ko) 2001-06-14 2002-06-14 나트륨 채널을 조절하기 위한 이미다졸 유도체
DE60206171T DE60206171T2 (de) 2001-06-14 2002-06-14 Kaliumkanal-modulierende imidazolderivate
NZ529741A NZ529741A (en) 2001-06-14 2002-06-14 Imidazole derivatives for modulating sodium channels
BR0210285-4A BR0210285A (pt) 2001-06-14 2002-06-14 Utilização de um composto, composto e composição farmacêutica
CA002449916A CA2449916A1 (fr) 2001-06-14 2002-06-14 Derives d'imidazoles modulant les canaux sodiques
HU0400195A HUP0400195A3 (en) 2001-06-14 2002-06-14 Imidazole derivatives for modulatig sodium channels, pharmaceutical compositions containing them and use of imidazole derivatives for producing pharmaceutical compositions having sodium channels modulating effect
JP2003504962A JP2005500297A (ja) 2001-06-14 2002-06-14 ナトリウムチャンネルを調節するイミダゾール誘導体
IS7067A IS2367B (is) 2001-06-14 2003-12-08 Imídasólafleiður til að stilla natríumgöng
NO20035553A NO20035553D0 (no) 2001-06-14 2003-12-12 Imidazol-derivater for modulering av natrium-kanaler
US11/281,864 US7402602B2 (en) 2001-06-14 2005-11-17 Imidazole derivatives modulating the sodium channels
US11/604,522 US20070099975A1 (en) 2001-06-14 2006-11-27 Imidazole derivatives modulating the sodium channels

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107820A FR2825926A1 (fr) 2001-06-14 2001-06-14 Derives d'imidazoles modulant les canaux sodiques
FR01/07820 2001-06-15

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10480977 A-371-Of-International 2002-06-14
US11/281,864 Division US7402602B2 (en) 2001-06-14 2005-11-17 Imidazole derivatives modulating the sodium channels
US11/604,522 Division US20070099975A1 (en) 2001-06-14 2006-11-27 Imidazole derivatives modulating the sodium channels

Publications (2)

Publication Number Publication Date
WO2002102375A2 WO2002102375A2 (fr) 2002-12-27
WO2002102375A3 true WO2002102375A3 (fr) 2003-09-25

Family

ID=8864329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/002039 Ceased WO2002102375A2 (fr) 2001-06-14 2002-06-14 Derives d'imidazoles modulant les canaux sodiques

Country Status (21)

Country Link
US (3) US7157483B2 (fr)
EP (1) EP1401432B1 (fr)
JP (1) JP2005500297A (fr)
KR (1) KR20040030672A (fr)
CN (1) CN1535148A (fr)
AT (1) ATE304354T1 (fr)
BR (1) BR0210285A (fr)
CA (1) CA2449916A1 (fr)
CZ (1) CZ297321B6 (fr)
DE (1) DE60206171T2 (fr)
DK (1) DK1401432T3 (fr)
ES (1) ES2249595T3 (fr)
FR (1) FR2825926A1 (fr)
HU (1) HUP0400195A3 (fr)
IS (1) IS2367B (fr)
MX (1) MXPA03011508A (fr)
NO (1) NO20035553D0 (fr)
NZ (1) NZ529741A (fr)
PL (1) PL366722A1 (fr)
RU (1) RU2296565C2 (fr)
WO (1) WO2002102375A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004210711B2 (en) * 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
AU2004293013B2 (en) * 2003-11-19 2011-04-28 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
CA2606499C (fr) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Composes thyromimetiques utilises pour traiter les maladies hepatiques graisseuses
AU2006263433B8 (en) 2005-06-29 2011-06-09 Immunogenesis, Inc. Phosphoramidate alkylator prodrugs
US20090291904A1 (en) * 2005-12-07 2009-11-26 Yoel Kashman Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
CA2630666A1 (fr) * 2005-12-07 2007-06-14 Sepal Pharma Ltd. Derives chimiques ameliores de jasmonate, compositions pharmaceutiques et procedes d'utilisation correspondants
US9284274B2 (en) 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
WO2008083101A1 (fr) 2006-12-26 2008-07-10 Threshold Pharmaceuticals, Inc. Promédicaments d'alkylation de phosphoramidate pour le traitement du cancer
US7883898B2 (en) * 2007-05-07 2011-02-08 General Electric Company Method and apparatus for measuring pH of low alkalinity solutions
US8188080B2 (en) * 2007-10-17 2012-05-29 Sanford-Burnham Medical Research Institute VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
CN102046240B (zh) 2008-03-25 2014-06-25 阿费克蒂斯药品公司 新的p2x7r拮抗剂及其应用
US8815892B2 (en) 2008-03-25 2014-08-26 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
MY158622A (en) * 2008-10-06 2016-10-31 Shikoku Chem 2-benzyl-4-(2,4-dichlorophenyl)-5-methylimidazole compound
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
JP5368244B2 (ja) * 2009-10-14 2013-12-18 四国化成工業株式会社 ２−（２，４−ジクロロベンジル）−４−アリール−５−メチルイミダゾール化合物
JP5368263B2 (ja) * 2009-11-04 2013-12-18 四国化成工業株式会社 ４−（２，４−ジクロロフェニル）−５−メチルイミダゾール化合物
JP5368271B2 (ja) * 2009-11-20 2013-12-18 四国化成工業株式会社 ４−（４−ビフェニリル）−２−（２，４−ジクロロベンジル）イミダゾールおよび表面処理液
BR112019010249A2 (pt) 2016-11-21 2019-09-10 Viking Therapeutics Inc método de tratamento de doença de armazenamento de glicogênio
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2024097171A1 (fr) * 2022-10-31 2024-05-10 Genep Inc. Composés imidazoles et leur utilisation en tant qu'inhibiteurs des canaux sodiques
WO2025231324A1 (fr) * 2024-05-02 2025-11-06 Genep Inc. Composés d'imidazole et leur utilisation en tant qu'inhibiteurs des canaux sodiques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057877A1 (fr) * 1999-03-26 2000-10-05 Euro-Celtique S.A. Pyrazoles, imidazoles, oxazoles, thiazoles et pyrroles aryle substitues et leurs utilisations
WO2000071120A1 (fr) * 1999-05-25 2000-11-30 Smithkline Beecham Corporation Composes antibacteriens
WO2001026656A2 (fr) * 1999-10-11 2001-04-19 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'heterocycles a 5 chainons et leur application comme inhibiteurs de monoamine oxydase
WO2001044201A1 (fr) * 1999-12-16 2001-06-21 Schering Corporation Antagonistes du recepteur y5 au neuropeptide y a imidazoles substituees

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1046248A (en) * 1962-08-02 1966-10-19 Benger Lab Ltd Substituted imidazoles
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
EP0786455B1 (fr) * 1994-09-26 2003-12-03 Shionogi & Co., Ltd. Derive imidazole
PT1036065E (pt) * 1997-12-04 2004-09-30 Allergan Inc Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
US6003118A (en) * 1997-12-16 1999-12-14 Acer Laboratories Inc. Method and apparatus for synchronizing clock distribution of a data processing system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057877A1 (fr) * 1999-03-26 2000-10-05 Euro-Celtique S.A. Pyrazoles, imidazoles, oxazoles, thiazoles et pyrroles aryle substitues et leurs utilisations
WO2000071120A1 (fr) * 1999-05-25 2000-11-30 Smithkline Beecham Corporation Composes antibacteriens
WO2001026656A2 (fr) * 1999-10-11 2001-04-19 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'heterocycles a 5 chainons et leur application comme inhibiteurs de monoamine oxydase
WO2001044201A1 (fr) * 1999-12-16 2001-06-21 Schering Corporation Antagonistes du recepteur y5 au neuropeptide y a imidazoles substituees

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HEERDING, D. A. ET AL: "1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001), 11(16), 2061-2065, XP001059006 *
LIPSHUTZ, BRUCE H. ET AL: "Protection of imidazoles as their [.beta.-(trimethylsilyl)ethoxy]methyl (SEM) derivatives", TETRAHEDRON LETT. (1986), 27(35), 4095-8, XP001053736 *
SUENAGA, K. ET AL: "Catharsitoxins from the Chinese remedy qiung laug", TETRAHEDRON LETTERS (2001), 42(40), 7079-7081, XP004317896 *
VENKATARAMAN, B. V. ET AL: "Structure-activity studies of new imidazolines on adrenoceptors of rat aorta and human platelets", NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL. (1991), 344(4), 454-63, XP001061258 *

Also Published As

Publication number Publication date
US7157483B2 (en) 2007-01-02
FR2825926A1 (fr) 2002-12-20
EP1401432B1 (fr) 2005-09-14
CN1535148A (zh) 2004-10-06
NO20035553D0 (no) 2003-12-12
IS7067A (is) 2003-12-08
EP1401432A2 (fr) 2004-03-31
KR20040030672A (ko) 2004-04-09
IS2367B (is) 2008-06-15
RU2004100843A (ru) 2005-04-10
DE60206171D1 (de) 2005-10-20
CZ297321B6 (cs) 2006-11-15
HUP0400195A3 (en) 2004-10-28
CZ20033550A3 (cs) 2005-05-18
WO2002102375A2 (fr) 2002-12-27
DK1401432T3 (da) 2006-02-06
DE60206171T2 (de) 2006-06-22
RU2296565C2 (ru) 2007-04-10
JP2005500297A (ja) 2005-01-06
CA2449916A1 (fr) 2002-12-27
NZ529741A (en) 2006-10-27
MXPA03011508A (es) 2004-03-18
US20040198792A1 (en) 2004-10-07
BR0210285A (pt) 2004-06-29
US7402602B2 (en) 2008-07-22
US20070099975A1 (en) 2007-05-03
US20060069146A1 (en) 2006-03-30
HUP0400195A2 (hu) 2004-07-28
PL366722A1 (en) 2005-02-07
ATE304354T1 (de) 2005-09-15
ES2249595T3 (es) 2006-04-01

Similar Documents

Publication Publication Date Title
WO2002102375A3 (fr) Derives d'imidazoles modulant les canaux sodiques
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU6703300A (en) Fungicides
IL193771A (en) Preparations that act as protein inhibitors deliver cholesterol ester
AU3850600A (en) Dalda analogs and their use
PL1685142T3 (pl) Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera
CA2336412A1 (fr) Medicament pour le traitement du diabete
WO2003051274A3 (fr) Derives de la benzodiazepine, leur preparation et leur utilisation
WO2003006443A3 (fr) Derives d'acide carboxylique, medicaments contenant ces composes, leur utilisation et leur production
HK1053833A1 (zh) 取代苯基法呢基转移酶抑制剂
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
WO2003053971A8 (fr) Antiviraux a base de pyridoquinoxaline
WO2003054001A3 (fr) Procede de preparation de derives d'echinocandines et leurs compositions
AU2002359150A1 (en) Therapeutic heterocycles
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
AU4424401A (en) Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
EP1026162A4 (fr) Agent anti-rhumatismal
WO2002072567A3 (fr) Nouveaux composes heterocycliques utiles dans le traitement des troubles allergiques inflammatoires; procede de leur preparation et compositions pharmaceutiques les contenant
EA200000068A3 (ru) Новые цианоиндольные соединения, являющиеся ингибиторами повторного захвата серотонина, способ их получения и фармацевтические композиции, содержащие их
WO2003091243A8 (fr) Derives ester d'un acide decahydroisoquinoline-3 carboxylique utiles en tant qu'analgesiques
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
GEP20063758B (en) Benzothia(Dia)Zine Derivatives and Method for Their Use as AMPA Modulators
MXPA05009122A (es) Derivados de acido benzoilureidopiridil-piperidin-y pirrolidin-carboxilico sustituido, metodo para su produccion y su uso.
WO2004035002A3 (fr) Composes de benzopyranone, compositions correspondantes et methodes de traitement ou de prevention du cancer
AU6902800A (en) Pyridomorphinans and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 158930

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 529741

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 028111842

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2449916

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/011508

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020037016257

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10480977

Country of ref document: US

Ref document number: 2003504962

Country of ref document: JP

Ref document number: 2002317251

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2003-3550

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002745529

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002745529

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-3550

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2002745529

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV2003-3550

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2002317251

Country of ref document: AU